FBLD 2008 Scientific Advisory Board

Daniel A. Erlanson

Daniel A. Erlanson is the co-inventor of a family of fragment-based drug discovery techniques, which he has used to discover leads against a variety of drug targets. He recently co-edited the first book to provide an overview of fragment-based approaches in drug discovery. Dr. Erlanson joined Sunesis Pharmaceuticals at its inception in 1998 and co-invented Tethering, which boosts proteins’ ability to capture ligands that bind weakly but specifically to sites of interest. Prior to Sunesis, he was a post doctoral fellow with James A. Wells at Genentech. Dr. Erlanson completed his Ph.D. in chemistry from Harvard University in the laboratory of Gregory L. Verdine and his BA in chemistry from Carleton College in Northfield, Minnesota.